Spinal Muscular Atrophy Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Type (Type 1, Type 2, Type 3, Type 4); Treatment (Gene Therapy, Drug Therapy, Others); Route of Administration (Oral, Intrathecal) and Geography

Report Code: TIPRE00024330 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Spinal muscular atrophy is a type of hereditary disease that affects the central & peripheral nervous system and voluntary muscle movement. It is linked to chromosome 5q (SMA) and caused by bi-allelic mutations in the SMN1 gene. It can lead to weakness and may cause death. Spinal muscular atrophy can be divided into type I, type II, type III, and type IV, depending upon variation in cause and symptoms observed. The treatment of SMA includes gene replacement therapy and drugs that may be administered to increase survival motor neuron protein levels.

MARKET SCOPE

The "Global Spinal Muscular Atrophy Treatment Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the spinal muscular atrophy treatment market with detailed market segmentation by disease type, treatment, route of administration, and geography. The report provides key statistics on the market status of the leading spinal muscular atrophy treatment market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •  Based on disease type, the global spinal muscular atrophy treatment market is segmented into type 1, type 2, type 3 and type 4.
  •  Based on treatment, the market is segmented into gene therapy, drug therapy and others.
  •  On the basis of route of administration, the market is bifurcated into oral and intrathecal.

MARKET DYNAMICS
Drivers:

  •  Growing awareness for spinal muscular atrophy (SMA), its diagnostics & treatment.
  •  Increase in the R & D activities to develop novel treatment regimens for rare diseases.
  •  Rapid technological advancements.
  •  Increase in the government initiatives to improve healthcare infrastructure.

Restraints:

  •  High cost of SMA treatment.
  •  Lack of skilled professionals for physiotherapy regimens & surgical procedures.
  •  Limited access to treatment of SMA.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The spinal muscular atrophy treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the spinal muscular atrophy treatment market in these regions.

IMPACT OF COVID-19ON SPINAL MUSCULAR ATROPHY TREATMENT MARKET

COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The ongoing pandemic has resulted in a worldwide healthcare crisis. Physicians and patients that visited hospitals for various treatments were at increased risk of contracting COVID-19; therefore, the government of various countries imposed lockdown and restrictive measures to prevent the transmission of infection, and despite the urgency to treat SMA patients, the delivery of treatment to individuals affected by SMA was impacted. The non-essential procedures were canceled or postponed, and only emergency procedures were allowed to be performed, impacting the SMA treatment market growth. However, the market may experience growth after the removal of restrictive measures in the forecast period.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the spinal muscular atrophy treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from spinal muscular atrophy treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for spinal muscular atrophy treatment in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the spinal muscular atrophy treatment market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  Novartis International AG
  •  Pfizer Inc.
  •  Biogen Inc.
  •  F. Hoffmann - La Roche Ltd
  •  Cytokinetics, Inc.
  •  Ionis Pharmaceuticals Inc.
  •  Natera, Inc
  •  Regeneron Pharmaceuticals Inc.
  •  Astellas Pharma Inc.
  •  PerkinElmer, Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Spinal Muscular Atrophy Treatment Market - By Disease Type
1.3.2 Spinal Muscular Atrophy Treatment Market - By Treatment
1.3.3 Spinal Muscular Atrophy Treatment Market - By Route of Administration
1.3.4 Spinal Muscular Atrophy Treatment Market - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. SPINAL MUSCULAR ATROPHY TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. SPINAL MUSCULAR ATROPHY TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. SPINAL MUSCULAR ATROPHY TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. SPINAL MUSCULAR ATROPHY TREATMENT - GLOBAL MARKET OVERVIEW
6.2. SPINAL MUSCULAR ATROPHY TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING

7. SPINAL MUSCULAR ATROPHY TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE TYPE
7.1. OVERVIEW
7.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
7.3. TYPE 1
7.3.1. Overview
7.3.2. Type 1 Market Forecast and Analysis
7.4. TYPE 2
7.4.1. Overview
7.4.2. Type 2 Market Forecast and Analysis
7.5. TYPE 3
7.5.1. Overview
7.5.2. Type 3 Market Forecast and Analysis
7.6. TYPE 4
7.6.1. Overview
7.6.2. Type 4 Market Forecast and Analysis
8. SPINAL MUSCULAR ATROPHY TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT
8.1. OVERVIEW
8.2. TREATMENT MARKET FORECASTS AND ANALYSIS
8.3. GENE THERAPY
8.3.1. Overview
8.3.2. Gene Therapy Market Forecast and Analysis
8.4. DRUG THERAPY
8.4.1. Overview
8.4.2. Drug Therapy Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. SPINAL MUSCULAR ATROPHY TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. ORAL
9.3.1. Overview
9.3.2. Oral Market Forecast and Analysis
9.4. INTRATHECAL
9.4.1. Overview
9.4.2. Intrathecal Market Forecast and Analysis

10. SPINAL MUSCULAR ATROPHY TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Spinal Muscular Atrophy Treatment Market Overview
10.1.2 North America Spinal Muscular Atrophy Treatment Market Forecasts and Analysis
10.1.3 North America Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Disease Type
10.1.4 North America Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Treatment
10.1.5 North America Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Route of Administration
10.1.6 North America Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Spinal Muscular Atrophy Treatment Market
10.1.6.1.1 United States Spinal Muscular Atrophy Treatment Market by Disease Type
10.1.6.1.2 United States Spinal Muscular Atrophy Treatment Market by Treatment
10.1.6.1.3 United States Spinal Muscular Atrophy Treatment Market by Route of Administration
10.1.6.2 Canada Spinal Muscular Atrophy Treatment Market
10.1.6.2.1 Canada Spinal Muscular Atrophy Treatment Market by Disease Type
10.1.6.2.2 Canada Spinal Muscular Atrophy Treatment Market by Treatment
10.1.6.2.3 Canada Spinal Muscular Atrophy Treatment Market by Route of Administration
10.1.6.3 Mexico Spinal Muscular Atrophy Treatment Market
10.1.6.3.1 Mexico Spinal Muscular Atrophy Treatment Market by Disease Type
10.1.6.3.2 Mexico Spinal Muscular Atrophy Treatment Market by Treatment
10.1.6.3.3 Mexico Spinal Muscular Atrophy Treatment Market by Route of Administration
10.2. EUROPE
10.2.1 Europe Spinal Muscular Atrophy Treatment Market Overview
10.2.2 Europe Spinal Muscular Atrophy Treatment Market Forecasts and Analysis
10.2.3 Europe Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Disease Type
10.2.4 Europe Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Treatment
10.2.5 Europe Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Route of Administration
10.2.6 Europe Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Spinal Muscular Atrophy Treatment Market
10.2.6.1.1 Germany Spinal Muscular Atrophy Treatment Market by Disease Type
10.2.6.1.2 Germany Spinal Muscular Atrophy Treatment Market by Treatment
10.2.6.1.3 Germany Spinal Muscular Atrophy Treatment Market by Route of Administration
10.2.6.2 France Spinal Muscular Atrophy Treatment Market
10.2.6.2.1 France Spinal Muscular Atrophy Treatment Market by Disease Type
10.2.6.2.2 France Spinal Muscular Atrophy Treatment Market by Treatment
10.2.6.2.3 France Spinal Muscular Atrophy Treatment Market by Route of Administration
10.2.6.3 Italy Spinal Muscular Atrophy Treatment Market
10.2.6.3.1 Italy Spinal Muscular Atrophy Treatment Market by Disease Type
10.2.6.3.2 Italy Spinal Muscular Atrophy Treatment Market by Treatment
10.2.6.3.3 Italy Spinal Muscular Atrophy Treatment Market by Route of Administration
10.2.6.4 Spain Spinal Muscular Atrophy Treatment Market
10.2.6.4.1 Spain Spinal Muscular Atrophy Treatment Market by Disease Type
10.2.6.4.2 Spain Spinal Muscular Atrophy Treatment Market by Treatment
10.2.6.4.3 Spain Spinal Muscular Atrophy Treatment Market by Route of Administration
10.2.6.5 United Kingdom Spinal Muscular Atrophy Treatment Market
10.2.6.5.1 United Kingdom Spinal Muscular Atrophy Treatment Market by Disease Type
10.2.6.5.2 United Kingdom Spinal Muscular Atrophy Treatment Market by Treatment
10.2.6.5.3 United Kingdom Spinal Muscular Atrophy Treatment Market by Route of Administration
10.2.6.6 Rest of Europe Spinal Muscular Atrophy Treatment Market
10.2.6.6.1 Rest of Europe Spinal Muscular Atrophy Treatment Market by Disease Type
10.2.6.6.2 Rest of Europe Spinal Muscular Atrophy Treatment Market by Treatment
10.2.6.6.3 Rest of Europe Spinal Muscular Atrophy Treatment Market by Route of Administration
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Spinal Muscular Atrophy Treatment Market Overview
10.3.2 Asia-Pacific Spinal Muscular Atrophy Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Disease Type
10.3.4 Asia-Pacific Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Treatment
10.3.5 Asia-Pacific Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Route of Administration
10.3.6 Asia-Pacific Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Spinal Muscular Atrophy Treatment Market
10.3.6.1.1 Australia Spinal Muscular Atrophy Treatment Market by Disease Type
10.3.6.1.2 Australia Spinal Muscular Atrophy Treatment Market by Treatment
10.3.6.1.3 Australia Spinal Muscular Atrophy Treatment Market by Route of Administration
10.3.6.2 China Spinal Muscular Atrophy Treatment Market
10.3.6.2.1 China Spinal Muscular Atrophy Treatment Market by Disease Type
10.3.6.2.2 China Spinal Muscular Atrophy Treatment Market by Treatment
10.3.6.2.3 China Spinal Muscular Atrophy Treatment Market by Route of Administration
10.3.6.3 India Spinal Muscular Atrophy Treatment Market
10.3.6.3.1 India Spinal Muscular Atrophy Treatment Market by Disease Type
10.3.6.3.2 India Spinal Muscular Atrophy Treatment Market by Treatment
10.3.6.3.3 India Spinal Muscular Atrophy Treatment Market by Route of Administration
10.3.6.4 Japan Spinal Muscular Atrophy Treatment Market
10.3.6.4.1 Japan Spinal Muscular Atrophy Treatment Market by Disease Type
10.3.6.4.2 Japan Spinal Muscular Atrophy Treatment Market by Treatment
10.3.6.4.3 Japan Spinal Muscular Atrophy Treatment Market by Route of Administration
10.3.6.5 South Korea Spinal Muscular Atrophy Treatment Market
10.3.6.5.1 South Korea Spinal Muscular Atrophy Treatment Market by Disease Type
10.3.6.5.2 South Korea Spinal Muscular Atrophy Treatment Market by Treatment
10.3.6.5.3 South Korea Spinal Muscular Atrophy Treatment Market by Route of Administration
10.3.6.6 Rest of Asia-Pacific Spinal Muscular Atrophy Treatment Market
10.3.6.6.1 Rest of Asia-Pacific Spinal Muscular Atrophy Treatment Market by Disease Type
10.3.6.6.2 Rest of Asia-Pacific Spinal Muscular Atrophy Treatment Market by Treatment
10.3.6.6.3 Rest of Asia-Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Spinal Muscular Atrophy Treatment Market Overview
10.4.2 Middle East and Africa Spinal Muscular Atrophy Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Disease Type
10.4.4 Middle East and Africa Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Treatment
10.4.5 Middle East and Africa Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Route of Administration
10.4.6 Middle East and Africa Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Spinal Muscular Atrophy Treatment Market
10.4.6.1.1 South Africa Spinal Muscular Atrophy Treatment Market by Disease Type
10.4.6.1.2 South Africa Spinal Muscular Atrophy Treatment Market by Treatment
10.4.6.1.3 South Africa Spinal Muscular Atrophy Treatment Market by Route of Administration
10.4.6.2 Saudi Arabia Spinal Muscular Atrophy Treatment Market
10.4.6.2.1 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Disease Type
10.4.6.2.2 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Treatment
10.4.6.2.3 Saudi Arabia Spinal Muscular Atrophy Treatment Market by Route of Administration
10.4.6.3 U.A.E Spinal Muscular Atrophy Treatment Market
10.4.6.3.1 U.A.E Spinal Muscular Atrophy Treatment Market by Disease Type
10.4.6.3.2 U.A.E Spinal Muscular Atrophy Treatment Market by Treatment
10.4.6.3.3 U.A.E Spinal Muscular Atrophy Treatment Market by Route of Administration
10.4.6.4 Rest of Middle East and Africa Spinal Muscular Atrophy Treatment Market
10.4.6.4.1 Rest of Middle East and Africa Spinal Muscular Atrophy Treatment Market by Disease Type
10.4.6.4.2 Rest of Middle East and Africa Spinal Muscular Atrophy Treatment Market by Treatment
10.4.6.4.3 Rest of Middle East and Africa Spinal Muscular Atrophy Treatment Market by Route of Administration
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Spinal Muscular Atrophy Treatment Market Overview
10.5.2 South and Central America Spinal Muscular Atrophy Treatment Market Forecasts and Analysis
10.5.3 South and Central America Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Disease Type
10.5.4 South and Central America Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Treatment
10.5.5 South and Central America Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Route of Administration
10.5.6 South and Central America Spinal Muscular Atrophy Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Spinal Muscular Atrophy Treatment Market
10.5.6.1.1 Brazil Spinal Muscular Atrophy Treatment Market by Disease Type
10.5.6.1.2 Brazil Spinal Muscular Atrophy Treatment Market by Treatment
10.5.6.1.3 Brazil Spinal Muscular Atrophy Treatment Market by Route of Administration
10.5.6.2 Argentina Spinal Muscular Atrophy Treatment Market
10.5.6.2.1 Argentina Spinal Muscular Atrophy Treatment Market by Disease Type
10.5.6.2.2 Argentina Spinal Muscular Atrophy Treatment Market by Treatment
10.5.6.2.3 Argentina Spinal Muscular Atrophy Treatment Market by Route of Administration
10.5.6.3 Rest of South and Central America Spinal Muscular Atrophy Treatment Market
10.5.6.3.1 Rest of South and Central America Spinal Muscular Atrophy Treatment Market by Disease Type
10.5.6.3.2 Rest of South and Central America Spinal Muscular Atrophy Treatment Market by Treatment
10.5.6.3.3 Rest of South and Central America Spinal Muscular Atrophy Treatment Market by Route of Administration

11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, KEY COMPANY PROFILES
12.1. NOVARTIS INTERNATIONAL
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PFIZER INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. BIOGEN INC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. F. HOFFMANN - LA ROCHE LTD
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. CYTOKINETICS, INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. IONIS PHARMACEUTICALS INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. NATERA, INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. REGENERON PHARMACEUTICALS INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. ASTELLAS PHARMA INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. PERKINELMER, INC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments

13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Novartis International
2. Pfizer Inc.
3. Biogen Inc.
4. F. Hoffmann - La Roche Ltd
5. Cytokinetics, Inc.
6. Ionis Pharmaceuticals Inc.
7. Natera, Inc.
8. Regeneron Pharmaceuticals Inc.
9. Astellas Pharma Inc.
10. PerkinElmer, Inc.
TIPRE00024330
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking